Tissue metabolic adaptability governs organ injury severity and recovery in inflammation. Despite this, treatments for myocardial metabolic failure in septic cardiomyopathy (SCM) are scarce. Our study explores how MacroD1 influences mitochondrial function and the NLRP3 inflammasome pathway via mono-ADP-ribosylation of related proteins, impacting SCM outcomes.